<DOC>
	<DOCNO>NCT00681733</DOCNO>
	<brief_summary>1 . To assess metabolic factor lean obese patient NASH . 2 . To compare efficacy pentoxifylline versus pioglitazone metabolic profile liver histology NASH patient .</brief_summary>
	<brief_title>Pentoxifylline Versus Pioglitazone In Non-Alcoholic Steatohepatiti ( NASH )</brief_title>
	<detailed_description>A total 40 patient biopsy proven NASH enrol . Inclusion criterion - Abdominal USG show diffusely echogenic liver suggestive fatty infiltration liver . - ALT &gt; 1.2 time upper limit normal &gt; 6 month . ( atleast three reading one month apart ) - Liver Biopsy show steatosis affect &gt; 10 % hepatocytes necroinflammatory activity , ballooning hepatocytes &amp; / fibrosis . Exclusion criterion - Alcohol intake 20g/wk - Evidence viral/ autoimmune hepatitis - PBC ( Primary biliary cirrhosis ) - Biliary obstrution - Wilson disease - Haemchromatosis - Decompensated cirrhosis - Drug ingestion follwing drug period 4 week past 6 week - Amiodarone - Methotrexate - Perhexiline - Glucocorticoids - Estrogens - Tamoxifen - Nifedipine - Diltiazem - Tamoxifen - DM Type I STUDY DESIGN The study divide two part Part A Part B . Part A - A cross-sectional study metabolic profile do enrollment detailed physical examination laboratory investigation certain specific test non-alcoholic steatohepatitis . - At enrollment follow characteristic included- - Prior history Diabetes , Hypertension , Dyslipidemia , Coronary artery disease . - Age , sex , weight , height , BMI ( body mass index ) , waist &amp; hip circumference . - USG abdomen - LFT - Fasting glucose , post-prandial blood sugar/oral GTT ( glucose tolerance test ) - Fasting insulin level - Fasting C- peptide - HOMA-IR ( Homeostasis Model Assessment-insulin resistance ) - Fasting lipid profile - Fasting TNF- α - Fasting Adiponectin - Fasting Leptin - Liver biopsy - Waist measure soft tape stand subject midway low rib iliac spine . - BMI every patient calculate . - Lean patient define BMI 18.5- 22.9 kg/m2 - Overweight ≥ 23- 24.9 kg/m2 - Obese ≥ 25 kg/m2 - Lean patient categorize 1 . Normal waist circumference ( &lt; 90cm men , &lt; 80 cm woman ) 2 . Abnormal waist circumference ( mention criterion ) - Insulin resistance calculate HOMA-IR - Fasting serum insulin ( μIU/ ml ) x Fasting serum glucose ( mmol/l ) ÷ 22.5 HOMA-IR &gt; 2 take insulin resistance . - TNF- α , adiponectin leptin measure ELISA method use standard kit . - Liver biopsy analyze pathologist time enrollment study . Histology report do method give Brunt et al.23 Part B . A Prospective Randomized Controlled Trial compare efficacy Pentoxyphylline versus Pioglitazone do . A total 40 NASH patient ( lean obese ) enrol . All advise dietary exercise protocol . Twenty patient randomized receive Pentoxifylline dose 1200mg/day 3 divided dos . Another twenty patient receive Pioglitazone dose 30 mg/day . The subject randomly assign receive either pentoxifylline pioglitazone ( randomization computer-generated ) . Patients follow liver biochemistry monthly interval initial 3 month subsequently 3 month interval . .Liver biopsy repeat end 6 month therapy . The pathologist blind drug administer NASH patient . Adverse event associate Pentoxifylline pioglitazone inquire record follow-up visit . The known side-effects Pentoxiphylline nausea , headache , vomit , dyspepsia , bloating , flushing , vertigo gastroesophageal reflux Pioglitazone myalgia , weight gain pedal edema . END POINT OF THE STUDY 1 . Repeat metabolic parameter liver biopsy do end 6 month . 2 . Improvement 50 % normalization aminotransferase end study compare baseline . 3 . Histology compare repeat liver biopsy .</detailed_description>
	<mesh_term>Pentoxifylline</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Patients biopsy proven NASH enrol . Abdominal USG show diffusely echogenic liver suggestive fatty infiltration liver . ALT &gt; 1.2 time upper limit normal &gt; 6 month . ( atleast three reading one month apart ) Liver Biopsy show steatosis affect &gt; 10 % hepatocytes necroinflammatory activity , ballooning hepatocytes &amp; / fibrosis . Alcohol intake 20g/wk Evidence viral/ autoimmune hepatitis PBC ( Primary biliary cirrhosis ) Biliary obstrution Wilson disease Haemchromatosis Decompensated cirrhosis Drug ingestion follwing drug period 4 week past 6 week Amiodarone , Methotrexate , Perhexiline , Glucocorticoids , Estrogens , Tamoxifen , Nifedipine , Diltiazem , Tamoxifen . DM Type I</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>NASH Pentoxifylline Pioglitazone</keyword>
</DOC>